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Extended Data 
Fig. 1 
Aurora-A phosphorylates H3S10 in S phase 
Roeschert_ED_Fig1.jpg a. Propidium-Iodide stained FACS profiles of IMR-5 cells synchronized at the G1/S boundary by a double-thymidine block (T0). Asynchronous cells are shown as controls. Cells were released from the block for 4 h into S phase, for 8 h into G2/M phase and for 14 h into G1 phase Data representative of 3 independent experiments with similar results. b. Fractionation of synchronized 
MYCN-amplified IMR-5 neuroblastoma cells. (Left): Immunoblots of equal aliquots of each fraction were probed for the indicated proteins. Data representative of 3 independent experiments with similar results. (Right): Quantitation of Aurora-A levels in each cell cycle phase. Shown is mean ± S.D. (n=3 independent experiments). c. MYCN ChIP at indicated loci in asynchronous IMR-5 cells treated for 4 h with 10058-F4 (100 µM). IgG control was used as control for antibody specificity. Data are presented as mean of technical triplicates. Data representative of 3 independent experiments with similar results.  d. Immunoblots of indicated proteins of IMR-5 cells either asynchronous, synchronized by double thymidine block into S or G2 phase or synchronized into mitosis by incubation with nocodazole for 16 h. Data representative of 2 independent experiments with similar results.  e. Radar blots documenting specificity of Aurora kinase inhibitors: 
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MLN8237, MK5108, AZD1152; data are from22. f. Quantification of pH3S10 staining in IMR-5 cells treated for 8 h with MLN8237 (1 µM) relative to control (DMSO) cells; each grey dot represents a cell. In S and G2 phase number of spots and in mitotic cells intensity of pH3S10 signal relative to DMSO is shown. Data are presented as mean ± S.D. (n≥614 cells per condition examined over 3 independent experiments). g. Quantification of pH3S10 staining of IMR-5 cells in S phase treated for 8 h with 100 nM MLN8237, 1 µM MK5108 or DMSO as control. Each dot represents one cell. Data are presented as mean ± S.D. (n≥147 cells per condition examined over 3 independent experiments). h. Quantification of pH3T3 intensity in IMR-5 cells treated for 8 h with 100 nM MLN8237, 100 nM AZD1152 or DMSO as control; each grey dot represents a cell. Shown is the mean ± S.D. (n≥47 cells per condition examined over 3 independent experiments). i.  Representative example pictures of 3 independent experiments with similar results. White line indicates 15 µm.  
Extended Data 
Fig. 2 
Effects of Aurora-A inhibition on H3.3 and pH3S10 
Roeschert_ED_Fig2.jpg a.  (Top): Ideogram illustrating the 50 bins with the strongest reduction in pH3S10 MLN8237 as compared to pH3S10 DMSO (blue rectangles). (Bottom): Levels of pH3S10 relative to total H3 along all chromosomes of S phase-synchronized IMR-5 cells treated for 4 h with 1 µM MLN8237 (red line) and DMSO (blue line) (n=2 independent experiments). b. pH3S10 ChIP at indicated loci in S phase synchronized IMR-5 cells treated for 4 h with 1 µM MLN8237. IgG control was used as control for antibody specificity. Data are presented as mean of technical triplicates Data representative of 3 independent experiments with 
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similar results  c.  Metagene plot of ChIP-Rx signal for histone H3.3 and pH3S10 in S phase-synchronized IMR-5 cells treated for 4 h with MLN8237 (1 µM) or DMSO. The graph is centered on the first nucleosome (“+1 dyad”) downstream of the TSS for N=14,340 genes. (n=2 independent replicates). d.  Browser tracks of MYCN, total RNAPII, H3.3 and pH3S10 of ChIP-Rx at a MYCN high (left) and low (right) bound locus. Nucleosome-free zone is indicated in grey. e.  Metagene plot of ChIP-Rx signal for histone H3 and histone H3.3 in S phase-synchronized IMR-5 cells treated for 4 h with 1 µM MLN8237 or DMSO. The signal is centered on the first nucleosome (“+1 dyad”) located downstream of the TSS for N=14,340 genes (n=3 independent experiments).  f.  Immunoblot of asynchronous SH-EP and SH-EP MYCN cells. Vinculin was used as loading control. Data representative of 3 independent experiments with similar results.  
Extended Data 
Fig. 3 
Aurora-A impacts RNAPII, splicing and R loop formation in S phase 
Roeschert_ED_Fig3.jpg a.  Metagene plot of all expressed genes (N=17,533) illustrating distribution of ChIP-Rx signal of total RNAPII within transcribed regions in S phase-synchronized IMR-5 cells treated for 4 h with 1 µM MLN8237, 1 µM MK5108 or solvent control (DMSO) (n=2 independent experiments). b. 2D Kernel density plot showing RNAPII traveling ratio in S phase-synchronized cells treated for 4 h with MLN8237 (1 µM) and in control (DMSO) cells (n=2 independent experiments). c. Metagene plot of ChIP-Rx signal for RNAPII pSer2 in S phase-synchronized IMR-5 cells treated for 2 h with MLN8237 (1 µM), MK5108 (1 µM) or DMSO. The signal is centered on the first nucleosome (“+1 dyad”) located within 300 nt downstream of the TSS for 
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n=14,340 genes (n=2 independent replicates). d. Browser tracks of MYCN, total RNAPII and RNAPII pSer2 of ChIP-Rx at FASN gene.   e.  Immunoblots of IMR-5 cells that were synchronized for the indicated cell cycle phase and treated with Pladienolide B (PlaB;1 µM), MLN8237 (1 µM), MK5108 (1 µM) or DMSO (4 h). Actin was used as loading control. Data representative of 3 independent experiments with similar results.  f. Definition of read categories; blue lines show where reads were mapped to; grey categories (exonic, spliced) reads represent mature mRNA, blue reads categories (exon-intron, intronic) represents non-spliced pre-mRNA, red categories (TSS, TES, TES-RT, intergenic) represents RNA without coding sequence. TSS: Transcription start site, TES: transcription end site. g. Diagram showing the setup of the 4sU-sequencing experiments in S phase-synchronized IMR-5 cells. h. Mean percentage of reads recovered in each category described in (f) (n=3 independent experiments). All treatments (PlaB, MK, MLN) significantly reduce the percentage of spliced reads relative to the “DMSO” control (p<1.0e-15 using paired two-tailed t test and Wilcoxon matched-pairs signed rank test). i.  DRIP using S9.6 antibody after 8 h of 1 µM MLN8237 or 1 µM PlaB treatment. Incubation with RNaseH1 and IgG were used as controls. Shown is the mean of technical triplicates. Data representative of 2 independent experiments with similar results. j.  (Left) DRIP using S9.6 antibody after 48 h of siAurora-A treatment. Shown is the mean of technical triplicates. (Right) Immunoblot of siRNA-transfected IMR-5 cells. Vinculin was used as loading control. Data 
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representative of 2 independent experiments with similar results.  
Extended Data 
Fig. 4 
Characterization of DNA replication and R-loop formation 
Roeschert_ED_Fig4.jpg a. Quantification of fork progression of SH-EP and SH-EP MYCN cells pretreated for 3 h with 100 nM or 1 µM MLN8237, 1 µM of AZD6738 or a combination (100 nM MLN8237 and 1 µM AZD6738). P-values were calculated using unpaired two-tailed t-test comparing two conditions (n≥168 fibers per condition were examined over 2 independent experiments).  b.  Annexin-V/PI FACS of IMR-5 or IMR-5 cells with inducible Aurora-A WT and T217D. After pre-treatment for 24 h with doxycycline to induce Aurora-A WT and T217D, cells were treated for 48 h with MLN8237 (100 nM), AZD6738 (1 µM) or both. Shown is the mean ± S.D. (n=3 independent experiments).  c. Annexin-V/PI FACS of IMR-5 treated for 48 h with MLN8237 (100 nM), CHIR-124 (1 µM) or both. Shown is the mean ± S.D. (n=3 independent experiments). d. DNA-RNA-Immunoprecipitation (DRIP) using S9.6 antibody of IMR-5 cells expressing a doxycycline inducible HA-RNaseH1. After 24 h doxycycline treatment, cells were treated for 8 h with 1 µM MLN8237. Incubation with RNaseH1 and IgG were used as controls for non-specific chromatin binding. Shown is the mean of technical triplicates. Data representative of 2 independent experiments with similar results.  Insert shows expression of HA-RNaseH1 in asynchronous IMR-5 cells upon doxycycline treatment for 24 h. Vinculin (VCL) was used as loading control. Data representative of 3 independent experiments with similar results.  e.  Metagene plot of ChIP-Rx signal for total RNAPII and H3.3 in S phase-synchronized RNaseH1-IMR-5 cells treated for 24 h with doxycycline to 
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induce RNaseH1 expression or EtOH (as control). Data show mean for N=3,731 genes. The signal is centered on the first nucleosome (“+1 dyad”) located within 300 nt downstream of the TSS (n=2 independent experiments).  f. Browser tracks of MYCN and total RNAPII of ChIP-Rx in (e) at FASN and NCL gene.  g. Metagene plot of ChIP-Rx signal for RNAPII pSer2 in S phase-synchronized RNaseH1-IMR-5 cells treated for 24 h with doxycycline (to induce RNaseH1 expression) or EtOH (as control). Data shown for n=14,340 genes. The signal is centered on the first nucleosome (“+1 dyad”) located within 300 nt downstream of the TSS for 14,340 genes (n=2 independent experiments). h. Quantification of PLA signals between RNAPII and PCNA in asynchronous RNaseH1-IMR-5 cells treated for 24 h with doxycycline to induce RNaseH1 expression. Each dot represents mean PLA signal of all cells in one well compared to solvent control. Shown is the mean ± S.D.. P-value was calculated using unpaired two-tailed t-test relative to DMSO control (n=3 independent experiments). i. Boxplot showing intensity of pKAP1 staining in mitotic cells upon the treatment with the indicated drugs (8 h) and induction of RNaseH1 expression for 24 h. P-value was calculated using two-tailed t-test between EtOH and Dox of each condition (n≥50 cells per condition were examined over 2 independent experiment). 
Extended Data 
Fig. 5 
Treatment is not toxic and tumor specific Roeschert_ED_Fig5.jpg a. Boxplot showing the concentration of indicated inhibitors in the tumor tissue of mice treated for 24 h or 5 days. N=4 mice (control, 24 h treatment), 5 mice (5 days treatment). b. Relative changes in body weight of mice treated with MLN8237 and AZD6738 compared to mice treated with 
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vehicle control. Shown is the mean ± S.D. N=42 mice (control), 43 mice (treated). c. Staining of tumor tissue with S9.6 incubated with different RNases to document specificity of S9.6. staining for R-loops (n=1 section for each experimental condition). d. Histology of proliferative gut tissue in untreated (top) and treated (bottom) mice showing H&E, Ki-67 and cleaved caspase 3 staining. N=2 mice (control), 3 mice treated). e. Representative MRI as well as sections of a tumor treated with a combination of MLN8237 and olaparib (N=3 animals were evaluated). f. MRI sections of the two long term-surviving mice at day 0 and after 7 days of treatment with the combination of AZD6738 (30 mg/kg) and MLN8237 (15 mg/kg). Dashed white lines indicate tumor circumference. g. P-values calculated using Mantel-Cox log-rank test comparing the survival of different groups shown in Figure 6c. 
Extended Data 
Fig. 6 
Therapeutic efficacy in Patient-derived xenograft models 
Roeschert_ED_Fig6.jpg a. Histology of representative tumor sections of MYCN-amplified PDX models treated as indicated. AZD6738 was administered at 50 mg/kg every day and MLN8237 at 7.5 mg/kg on a 5 days on, 2 days off schedule. Shown are stainings from tumors recovered after treatment for 14 days. Each group comprises three animals. b. Box plot showing quantification of R-loop-, γH2AX- and cleaved caspase 3-positive cells in tumor sections. P-values were calculated using unpaired two-tailed t-test using Welch’s correction (n≥9 sections from animals described in panel (a) were evaluated).  c. Relative changes in tumor volume of four MYCN non-amplified PDX models upon treatment with the indicated inhibitors. Shown is the mean ± S.E.M. N indicates the animal number for each experimental cohort. P-values comparing 
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control and combination (indicated with a black dashed line) were calculated using unpaired two-sided t-test. 
Extended Data 
Fig. 7 
Aurora-A/ATR inhibition engages the immune system 
Roeschert_ED_Fig7.jpg a. GSEA signatures showing response of a hallmark gene set indicating Interferon gamma response in the TH-MYCN (top) and a PDX (bottom) model. b. (Top): Representative pictures by flow cytometry showing cell gating. (Bottom): Populations of CD45+ immune cells in the tumor microenvironment after treatment of TH-MYCN mice with the combination of AZD6738 (25 mg/kg) and MLN8237. Shown is the mean ± S.E.M.. Significance was calculated using unpaired two-tailed t-test (N=4 animals from each condition were evaluated). c. Histology of representative tumor sections showing NKp46-positive cells and pSTAT1 in tumors of TH-MYCN mice treated with combined Aurora-A/ATR inhibition. N=4 mice (control, 24 h treatment), 5 mice (5 days treatment). d.  Relative changes in tumor volume of subcutaneous xenografts in nude mice after treatment with vehicle or the combination of MLN8237 and AZD6738 (25 mg/kg). Shown is the mean ± S.E.M. (N=5 animals per group). e.  Bar graph showing the survival of allograft mice treated with MLN8237 and AZD6738. Shown is the mean ± S.E.M. (N=4 animals per group). 
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Amplification of MYCN is the driving oncogene in a subset of high-risk 45 
neuroblastoma. The MYCN protein and the Aurora-A kinase form a complex during S 46 
phase that stabilizes MYCN. Here we show that MYCN activates Aurora-A on 47 
chromatin, which phosphorylates histone H3 at serine 10 in S phase, promotes the 48 
deposition of histone H3.3 and suppresses R-loop formation. Inhibition of Aurora-A 49 
induces transcription-replication conflicts and activates the Ataxia telangiectasia and 50 
Rad3 related (ATR) kinase, which limits double-strand break accumulation upon 51 
Aurora-A inhibition. Combined inhibition of Aurora-A and ATR induces rampant 52 
tumor-specific apoptosis and tumor regression in mouse models of neuroblastoma, 53 
leading to permanent eradication in a subset of mice. The therapeutic efficacy is due 54 
to both tumor cell-intrinsic and immune cell-mediated mechanisms. We propose that 55 
targeting the ability of Aurora-A to resolve transcription-replication conflicts is an 56 
effective therapy for MYCN-driven neuroblastoma (141 words).  57 
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Introduction 58 
Deregulated expression of one of the three members of the MYC family of oncogenes is 59 
observed in the majority of all human tumors and can drive tumorigenesis in many entities1. 60 
Tumors driven by multiple oncogenes depend on elevated MYC expression, arguing that 61 
strategies that target MYC function may have a large therapeutic impact2. Of the three family 62 
members, the neuronal paralogue, MYCN, has been implicated in the genesis of a broad 63 
range of predominantly neuroendocrine and pediatric tumors3. A paradigm example is 64 
neuroblastoma, in which amplification of MYCN drives the development of a subset of high-65 
risk tumors with poor prognosis, establishing an urgent need for therapeutic strategies that 66 
target MYCN function. 67 
MYC proteins are transcription factors that bind to the vast majority of all active promoters 68 
and many enhancers, with promoter occupancy paralleling that by RNA polymerase II 69 
(RNAPII). Consistent with these observations, they exert widespread effects on both the 70 
function and the composition of the basal transcription machinery and can globally release 71 
RNAPII from core promoters4-9. In marked contrast, the effects of MYC proteins on gene 72 
expression are typically weak and the expression of most MYC-bound genes is not 73 
detectably altered. These observations raise the possibility that MYC proteins have critical 74 
oncogenic functions that are unrelated to their effects on gene expression10. 75 
We have previously identified a complex of MYCN with the Aurora-A kinase and shown that 76 
complex formation stabilizes MYCN in neuroblastoma, since Aurora-A binds immediately 77 
adjacent to a major phosphodegron of MYCN and antagonizes recognition of the degron by 78 
the FBXW7 ubiquitin ligase11. As consequence, a class of Aurora-A ligands that distort the 79 
kinase domain and disrupt the Aurora-A/MYCN complex destabilize MYCN12-14. Conversely, 80 
MYCN stabilizes an active conformation of Aurora-A that is capable of substrate recognition, 81 
hence binding of MYCN, like that of TPX2, induces Aurora-A kinase activity14. During the cell 82 
cycle, MYCN predominantly forms a complex with Aurora-A during S phase and antagonizes 83 
the binding of MYCN to co-factors that are required for MYCN-dependent transcriptional 84 
activation15. Furthermore, stabilization of MYCN favors promoter-proximal transcription 85 
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termination via the recruitment of mRNA de-capping factors8. Collectively, the data suggest 86 
that complex formation with Aurora-A has a critical role during S phase to limit MYCN-87 
dependent transcription elongation and co-ordinate it with DNA replication15. Here we have 88 
clarified the mechanisms underlying these observations and show that they can be exploited 89 
for an effective therapy of MYCN-driven neuroblastoma.  90 
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Results 91 
Aurora-A binds together with MYCN to chromatin in S phase 92 
In neuroblastoma cells, MYCN complexes with Aurora-A during S phase15. To determine the 93 
subcellular localization of MYCN/Aurora-A complexes, we fractionated extracts of MYCN-94 
amplified IMR-5 neuroblastoma cells that had been synchronized by double-thymidine block 95 
and released for 4 h into S, 8 h into G2/M or 14 h into G1 phase (Extended Data Figure 1a). 96 
These experiments showed that approximately 70% of the cellular pool of Aurora-A was 97 
associated with chromatin during S phase, although expression of the known mitotic 98 
chromatin anchor of Aurora-A, TPX2, was low in S compared to G2/M phase (Extended Data 99 
Figure 1b)16. Incubation of S phase-synchronized cells for 4 h with 10058-F4, which disrupts 100 
heterodimers of MYC or MYCN with MAX6,17,18, reduced chromatin association of both MYCN 101 
and Aurora-A by 50%, arguing that MYCN stabilizes a significant fraction of the cellular pool 102 
of Aurora-A on chromatin (Figure 1a, Extended Data Figure 1c). Notably, MYCN that was 103 
released from chromatin by 10058-F4 did not accumulate in the nucleoplasm, since 104 
association with MAX protects MYC from ubiquitin-mediated degradation19. 105 
 106 
Aurora-A phosphorylates H3S10 in S phase 107 
Complex formation of Aurora-A with MYCN stabilizes MYCN11 and activates Aurora-A 108 
kinase14. Aurora-A localized at spindle poles autophosphorylates at T288 during mitosis 20, 109 
but we did not detect T288 phosphorylation during S phase (Extended Data Figure 1d). 110 
Aurora-A can phosphorylate Ser10 of histone H321. Indeed, immunofluorescence 111 
experiments using a specific Aurora-A inhibitor, MLN8237 (Alisertib; Extended Data Figure 112 
1e)22,23, showed that Aurora-A was required for H3S10 phosphorylation (pH3S10) in S and, 113 
to a lesser degree, in G2 phase (Figure 1b and Extended Data Figure 1f). A second Aurora-A 114 
inhibitor, MK5108, caused a similar, albeit weaker reduction in pH3S10 in S phase (Extended 115 
Data Figure 1g), consistent with its weaker reduction in Aurora-A autophosphorylation12,24. 116 
Phosphorylation of H3S10 did not require Aurora-A in mitotic cells (Figure 1b)25. Conversely, 117 
inhibition of Aurora-B using AZD1152 (Barasertib)26 blocked pH3S10 in mitosis but had little 118 
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effect in S and G2 phase (Figure 1c). Furthermore, phosphorylation of histone H3 at 119 
threonine 3, which occurs in mitosis and depends on Aurora-B, was blocked by AZD1152, 120 
but only weakly affected by MLN8237 (Extended Data Figure 1h,i)27. 121 
 122 
Aurora-A controls histone H3.3 incorporation 123 
To determine how Aurora-A-dependent phosphorylation of histone H3S10 impacts on 124 
chromatin structure at promoters, we performed spike-in chromatin-immunoprecipitation 125 
coupled with sequencing (ChIP-Rx sequencing) experiments from cells that were released 126 
from a double-thymidine block for 4 h in the presence of MLN8237. Notably, inhibition of 127 
kinase activity and disruption of MYCN/Aurora-A complexes by MLN8237 occur at different 128 
IC50 values
12. We therefore performed all ChIP-sequencing effects after exposure to 1 µM 129 
MLN8237, which is sufficient to induce both effects. This showed that inhibition of Aurora-A 130 
broadly suppressed pH3S10 throughout the genome, including notable decreases in pH3S10 131 
levels at peri-centromeric regions (Extended Data Figure 2a). Metagene analysis and ChIP 132 
experiments at individual MYCN-bound promoters showed that Aurora-A inhibition also 133 
decrease pH3S10 levels immediately adjacent to MYCN binding sites in active promoters 134 
(Extended Data Figure 2b,c,d). In neuroblastoma, MYCN, but not MYC, enhances the 135 
incorporation of a histone 3 variant, histone H3.3, into promoters, which can also be 136 
phosphorylated at S1028. In contrast to bulk histone H3.1, H3.3 is deposited in a replication-137 
independent manner and marks, among others, particularly active genes and their 138 
promoters29. Inhibition of Aurora-A led to a decrease in the deposition of histone H3.3, while 139 
deposition of bulk histone, which occurs after passage of the replication fork, increased in 140 
response to MLN8237 inhibition (Extended Data Figure 2e). Stratification of promoters by 141 
MYCN occupancy showed that MYCN-bound promoters were characterized by a 142 
nucleosome-depleted zone around the transcription start site and that MLN8237 decreased 143 
histone H3.3 occupancy and H3S10 phosphorylation predominantly at the position of the +1 144 
nucleosome (Figure 1d). In contrast, promoters with low MYCN binding showed only small 145 
MLN8237-dependent changes in H3.3 and H3S10 occupancy at specific positions around 146 
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the transcription start site (Figure 1e). To demonstrate directly that these effects were 147 
specific for MYCN, we constitutively expressed MYCN in SH-EP cells, which express 148 
endogenous MYC; since MYCN suppresses endogenous MYC, this leads to a stable switch 149 
from MYC to MYCN expression (Extended Data Figure 2f)8. ChIP experiments showed that 150 
MYCN enhanced histone H3S10 phosphorylation and promoted histone H3.3 incorporation 151 
and inhibition of Aurora-A blocked both processes at multiple MYCN-bound promoters 152 
(Figure 1f). 153 
 154 
To determine how these alterations in chromatin structure impact on RNAPII in S phase-155 
synchronized cells, we performed ChIP-Rx sequencing using antibodies directed against 156 
total RNAPII. Metagene analyses showed that inhibition of Aurora-A caused a global 157 
decrease in the amount of elongating RNAPII (p<0.0001), but not of RNAPII localized 158 
proximal to the promoter (Extended Data Figure 3a) and a corresponding increase in the 159 
ratio of promoter-bound to elongating RNAPII ("traveling ratio") (Extended Data Figure 3b). 160 
ChIP-Rx using antibodies that specifically recognize elongating RNAPII (RNAPII-pSer2) 161 
showed that RNAPII-pSer2 accumulated in a broad zone downstream of the TSS upon 162 
Aurora-A inhibition (Extended Data Figure 3c,d). Stratification of promoters by MYCN 163 
occupancy showed that RNAPII accumulation in response to MLN8237 was specific for 164 
MYCN-bound promoters (Figure 2a,b) and that the degree of accumulation correlated with 165 
MYCN occupancy (Figure 2c). The finding agrees with a previous demonstration that H3S10 166 
phosphorylation promotes pause-release of RNAPII 30. 167 
 168 
Aurora-A inhibition induces transcription-replication conflicts 169 
To understand the mechanisms underlying this perturbance in RNAPII function, we initially 170 
tested the impact of Aurora-A inhibition on RNA splicing, since Aurora-A has been implicated 171 
in cell cycle-dependent control of mRNA splicing31 and RNAPII accumulates at the first 172 
exon/intron boundary upon an impairment of spliceosome function32. Consistently, inhibition 173 
of Aurora-A in S phase, but not in other phases of the cell cycle, led to a decrease in SF3B1 174 
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phosphorylation at residues pT313 and pT328, which are phosphorylated in active 175 
spliceosomes (Extended Data Figure 3e)33. However, compared to an inhibitor of 176 
spliceosome, Pladienolide B (PlaB), inhibition of Aurora-A had only a small effect on overall 177 
splicing efficiency in S phase, as demonstrated by sequencing nascent RNA immediately 178 
after a 15 min pulse of 4-thiouridine (4sU) or after a chase of 2 h (Extended Data Figure 179 
3f,g,h). Since chromatin compaction marked by pH3S10 antagonizes R-loop formation34, we 180 
next performed DNA-RNA immunoprecipitation (DRIP)-assays using an antibody that 181 
recognizes RNA/DNA-hybrids (S9.6). These assays showed that inhibition of Aurora-A led to 182 
large increases of R-loops at all active and MYCN-bound promoters that we tested (Figure 183 
2d). No R-loop accumulation was observed at transcriptionally silent intergenic and 184 
centromeric sequences, despite large decreases in pH3S10 levels, consistent with the fact 185 
that R-loop formation requires active transcription (Figure 2d). R-loops did not accumulate in 186 
response to the Aurora-B inhibitor AZD1152 (Figure 2e) and only weakly in response to 187 
spliceosome inhibition by PlaB (Extended Data Figure 3i). siRNA-mediated depletion of 188 
Aurora-A also induced R-loop accumulation (Extended Data Figure 3j). To test whether 189 
Aurora-A inhibition impedes replication fork progression, we performed proximity-ligation 190 
assays (PLAs) using antibodies directed against RNAPII and proliferating cell nuclear 191 
antigen (PCNA), which forms the sliding clamp of DNA polymerase35 . These assays showed 192 
a significant increase in the number of foci upon inhibition of Aurora-A, which was sensitive 193 
to inhibition of CDK9, demonstrating that inhibition of Aurora-A causes transcription-194 
replication conflicts (Figure 2f)12. 195 
 196 
Aurora-A inhibition activates ATR 197 
Consistent with these observations, inhibition of Aurora-A in S phase, but much less in G2 198 
phase, induced ATR-dependent phosphorylation of serine 33 of replication protein A (Figure 199 
3a) and of serine 345 of the CHK1 kinase (Figure 3b)36. Notably, these data and our own 200 
previous observations15 show that increases in CHK1 phosphorylation required exposure of 201 
cells to elevated concentrations of MLN8237. Similar differences between ATR activity 202 
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towards RPA and CHK1 have been noted before and indicate that MLN8237 at low doses 203 
affects the stability of replication forks, but only at elevated concentrations causes CHK1-204 
mediated cell cycle arrest and DNA repair37. We therefore directly assessed the effect of 205 
Aurora-A and ATR on replication fork progression and we performed fiber assays, which 206 
showed that inhibition of Aurora-A significantly reduced replication fork speed (Figure 3c,d). 207 
Concomitant inhibition of Aurora-A and ATR using an inhibitor that is currently being explored 208 
in multiple clinical trials, AZD673838,39, led to further slow-down in fork progression, which 209 
exceeded that induced by gemcitabine, a known inhibitor of fork progression (Figure 3c,d). 210 
Comparison of SH-EP cells with SH-EP-MYCN cells showed that the decrease was much 211 
more pronounced in cells expressing MYCN (Extended Data Figure 4a). To support the 212 
argument that the induction of transcription-replication conflicts underlies the therapeutic 213 
effects in vivo, we used a combination of Aurora-A and PARP1 inhibition as a second 214 
strategy to induce transcription-replication conflicts. Inhibition of PARP1, which modulates 215 
fork progression and senses replication stress40, caused transcription-replication conflicts 216 
(Figure 3e) and decreased fork speed when combined with MLN8237 (Figure 3f,g). 217 
 218 
Upon replication stress, ATR inhibits origin firing and stabilizes stalled replication forks; as 219 
consequence, inhibition of ATR conflicts in stressed cells leads to formation of double-strand 220 
breaks41,42. Microscopy-based cytometry confirmed that inhibition of ATR using AZD6738 221 
strongly enhanced DNA synthesis and accelerated the passage through S phase, 222 
irrespective of the presence of MLN8237 (Figure 4a). Co-incubation of cells with MLN8237 223 
and AZD6738 strongly enhanced the number of cells showing elevated phosphorylation of 224 
γH2AX, which is a target of several DNA-damage-induced kinases, and of KAP1, a specific 225 
substrate of the ATM kinase that is activated at double-strand breaks, in the G2 phase of the 226 
cell cycle (Figure 4a,b). Inhibition of ATR enhanced the pro-apoptotic activity of MLN8237 in 227 
three MYCN-amplified neuroblastoma cell lines, but had little effect in three MYCN non-228 
amplified lines (Figure 4c). The effect of MLN8237 was on-target, since expression of 229 
Aurora-A T217D, a point mutant allele that has reduced affinity to MLN823743,44, suppressed 230 
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apoptosis in IMR-5 cells (Extended Data Figure 4b). Inhibition of Aurora-A also enhanced the 231 
pro-apoptotic effect of a CHK1 inhibitor, CHIR-12445 (Extended Data Figure 4c). We 232 
concluded that Aurora-A is required to prevent transcription-replication conflicts in MYCN-233 
amplified neuroblastoma cells and that inhibition of Aurora-A enhances the dependence of 234 
MYCN-amplified cells on the ATR kinase for maintaining genomic stability and survival. 235 
 236 
Aurora-A enables transcription termination in S phase 237 
To clarify the role of R-loops in coordinating transcription elongation with DNA replication, we 238 
expressed doxycycline-inducible RNAseH1 in MYCN-amplified cells and established that this 239 
reduced the MLN8237-induced accumulation of R-loops at active promoters (Extended Data 240 
Figure 4d). Removal of R-loops strongly enhanced histone H3.3 incorporation downstream of 241 
MYCN-binding sites arguing that the +1 nucleosome is stabilized. This correlated with 242 
stalling of RNAPII downstream of the transcription start sites of MYCN-bound promoters 243 
(Extended Data Figure 4e,f,g), but had no significant effects on the occurrence of 244 
transcription-replication conflicts (Extended Data Figure 4h). However, removal of R-loops by 245 
RNAseH1 strongly suppressed the accumulation of cells with high levels of DNA damage in 246 
mitosis after Aurora-A or Aurora-A/ATR inhibition, arguing that removal of R-loops facilitates 247 
the resolution of these conflicts (Extended Data Figure 4i). To limit R-loop accumulation, 248 
MYCN recruits mRNA decapping factors, which terminate transcription close to promoters8,46. 249 
Consistently, inhibition of Aurora-A antagonized the association of two de-capping factors, 250 
DCP1 and EDC4, with MYCN-bound promoters in S phase (Figure 4d). Collectively, the data 251 
argue that MLN8237-induced R-loop formation restricts the accessibility of nascent mRNA 252 
for transcription termination factors and thereby undermines the ability of MYCN to terminate 253 
transcription and prevent transcription-replication conflicts. 254 
 255 
Aurora-A/ATR treatment causes tumor-specific DNA damage 256 
As a single agent, MLN8237 has therapeutic efficacy in the TH-MYCN transgenic model of 257 
neuroblastoma47 at a dose of 30 mg/kg, which is the maximum tolerated dose12. Similarly, 258 
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clinical trials of neuroblastoma and MYCN-driven neuroendocrine prostate carcinoma 259 
patients show limited activity of MLN8237 which is in part due to dose-limiting toxicity48-50. To 260 
explore whether the MLN8237-induced dependence on ATR can be exploited to improve the 261 
efficacy of MLN8237 in MYCN-amplified neuroblastoma, we evaluated the efficacy of 262 
15 mg/kg MLN8237 given in combination with 25-30 mg/kg of AZD6738. Mass spectrometry 263 
of tissue samples showed that these dose lead to levels between 4 and 8 µmoles/kg body 264 
weight for each drug (Extended Data Figure 5a). At these doses, no toxicity was detectable 265 
using either MLN8237 or AZD6738 alone or with these drugs used in combination, in animals 266 
with palpable (approximately 1 cm diameter) tumors (Extended Data Figure 5b). We 267 
administered drugs for 32 days and assessed responses to treatment at day 1 and 5 on 268 
study. 269 
 270 
Control tumors in the TH-MYCN model feature the typical architecture of human 271 
neuroblastoma with tightly packed cells arranged in a vaguely lobular or nesting pattern, thin 272 
fibrovascular septa and occasional areas of hemorrhage (Figure 5a)47. Nuclear chromatin 273 
was finely dispersed with few and inconspicuous nuclei and fragmented nuclei were 274 
frequently observed. Numerous mitoses and a high Ki67-labelling index illustrate the strong 275 
proliferative nature of these neoplasms (Figure 5a). Tumors treated with a combination of 276 
MLN8237 and AZD6738 underwent a rapid and profound regressive change with 277 
architectural disintegration, expansion of hemorrhage and increased cell death (Figure 5a,b). 278 
The latter is evidenced by necrotic cell debris and an increase of tumor cells with fragmented 279 
nuclei (Figure 5a). 280 
 281 
Immunohistochemistry confirmed that combined Aurora-A and ATR inhibition strongly 282 
decreased pH3S10 levels in non-mitotic cells (Figure 5c,d) and led to a significant increase in 283 
R-loop formation (Figure 5a,b and Extended Data Figure 5c). Consistent with the responses 284 
observed in tissue culture, Ki67-positivity remained unchanged upon treatment, indicating an 285 
absence of cell cycle arrest in response to Aurora-A/ATR inhibition (Figure 5a). In contrast, 286 
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the number of cells staining positive for phosphorylated γH2AX, of 53BP1 and of 287 
phosphorylated KAP1 strongly increased in treated animals (Figure 5a,b). In addition, we 288 
noted a large increase in the number of cells that stained positive for cleaved caspase 3, 289 
indicating that tumor cells underwent rampant apoptosis in response to Aurora-A/ATR 290 
inhibition (Figure 5a,b). Notably, apoptosis induced by Aurora-A/ATR inhibition was tumor 291 
cell-specific, since no apoptosis was induced in the adjacent kidney tissue as well as in 292 
proliferative gut tissue (Figure 5a and Extended Data Figure 5d). 293 
 294 
Aurora-A/ATR treatment causes tumors regression and greatly extends lifespan 295 
As single agents, both MLN8237 and AZD6738 had variable effects on tumor progression; in 296 
contrast, the combination of both drugs led to robust tumor regression in 7/8 treated tumors 297 
(Figure 6a,b). Combining MLN8237 with the PARP1 inhibitor, olaparib, also led to 298 
widespread apoptosis in tumors and induced tumor regression, supporting the view that 299 
replication-transcription conflicts are causative for these effects (Figure 6b and Extended 300 
Data Figure 5e). To assess survival benefit, we treated mice for a maximum of 32 days 301 
before withdrawal of the drugs. Whereas all mice treated with either MLN8237 or AZD6738 302 
as single agents died while still on treatment, all mice treated with the combination of 303 
MLN8237 and AZD6738 survived until the end of treatment. Mice treated with MLN8237 and 304 
25 mg/kg AZD6738 survived for up to 21 days after cessation of therapy. Increasing the dose 305 
of AZD6738 to 30 mg/kg as a single agent provided no additional treatment benefit but 306 
further prolonged survival in combination with MLN8237, with two out of eight mice remaining 307 
tumor-free for up to 150 days after cessation of therapy, indicating a dose-related impact on 308 
long-term survival and cure in a subset of treated mice (Figure 6c and Extended Data Figure 309 
5f,g). 310 
 311 
To test this regimen in human tumor samples, we treated four MYCN-amplified and four 312 
MYCN non-amplified patient-derived xenografts (PDX) of neuroblastoma with MLN8237, 313 
AZD6738 or the combination of both drugs. Tumors recovered at the end of the treatment 314 
 23
period showed similar morphological alterations as described for the TH-MYCN mouse 315 
model (Extended Data Figure 6a). As in the TH-MYCN model, combining Aurora-A and ATR 316 
inhibition led to an accumulation of R-loops (Extended Data Figure 6a,b). Neither single nor 317 
combined Aurora-A or ATR inhibition altered the fraction of Ki67-positive cells, while they 318 
caused additive or synergistic increases in the number of tumor cells staining positive for 319 
phosphorylated γH2AX or undergoing apoptosis (Extended Data Figure 6a,b). In mice 320 
bearing MYCN-amplified tumors, the combined inhibition of Aurora-A and ATR suppressed 321 
the growth of three out of four tumors better than the best single treatment and caused 322 
regression in two tumors (Figure 7a). Combining both inhibitors was more effective than 323 
single treatment and cause regression in one of four MYCN non-amplified tumors (Extended 324 
Data Figure 6c). 325 
 326 
Aurora-A/ATR treatment engages the immune system 327 
While treatment responses of PDX models reflected the responses in the TH-MYCN models, 328 
they were generally weaker in the PDX models. To identify possible causes of this difference, 329 
we performed RNA sequencing of control and treated tumors in the transgenic model as well 330 
as in the PDX model. Gene set enrichment analysis (GSEA)51 showed a rapid induction of 331 
multiple genes involved in cytokine signaling, in particular via interferon-mediated pathways 332 
(Extended Data Figure 7a). This transcriptional response was not observed in the PDX 333 
model, indicating that it depends on an interaction of tumor cells with cells of the immune 334 
system (Extended Data Figure 7a). These observations are consistent with previous 335 
demonstrations that MYC proteins exert an immune-suppressive effect via the suppression 336 
of cytokine-dependent signaling pathways52. DNA damage activates the interferon and NF-337 
kB pathways via cGAS/STING53 and immunohistochemistry of tumors from the TH-MYCN 338 
model documented activation of cGAS/STING in parallel with infiltration of immune cells 339 
(Figure 7b,c). FACS analyses and histology confirmed an increased number of immune cells 340 
expressing the lymphocyte common antigen (CD45), which included an increase in the 341 
number of natural killer cells, in the tumor environment (Extended Data Figure 7b,c). In 342 
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addition, histology showed activation of STAT1 in response to treatment (Extended Data 343 
Figure 7c). To test whether engagement of the host immune system is relevant for the 344 
therapeutic response to Aurora-A/ATR inhibition, we injected tumor cells derived from the 345 
TH-MYCN mice into either immunocompetent syngeneic 129SvJ mice, immune suppressed 346 
nude mice lacking T cells or strongly immunodeficient NSG mice (lacking B-, T and NK cells) 347 
and monitored their growth. Tumors grew rapidly upon transplantation in either NSG, nude or 348 
129SvJ mice (Figure 7d and Extended Data Figure 7d). However, whilst treatment with 349 
MLN8237/AZD6738 dramatically slowed tumor growth in transplanted syngeneic mice, it had 350 
much weaker effects upon transplantation into immune-deficient (NSG) (Figure 7d). 351 
Treatment response was also weaker in nude mice, arguing that T-lymphocytes contribute to 352 
its efficacy (Extended Data Figure 7d). The differences in tumor growth were reflected in 353 
overall survival of treated mice (Extended Data Figure 7e). We concluded that combined 354 
Aurora-A/ATR inhibition engages the host immune system for tumor eradication. 355 
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Discussion 356 
We had previously shown that the MYCN protein forms a complex with the Aurora-A kinase 357 
during the S phase in neuroblastoma cells, but its molecular function and how it can be 358 
exploited for therapy had remained unclear. Here we have shown that MYCN recruits 359 
Aurora-A to chromatin in S phase, where it phosphorylates H3S10, and promotes the 360 
incorporation of histone H3.3 into promoters, thereby antagonizing R-loop accumulation 361 
(Figure 7e). R-loop formation limits the accessibility of nascent mRNA for splicing and for 362 
mRNA decapping factors, which enable promoter-proximal termination46. In addition, 363 
stabilization of the first nucleosome may promote premature polyadenylation and 364 
transcription termination in the first intron54. In neuroblastoma, Aurora-A has catalytic 365 
functions, but also binds to and stabilizes MYCN complexes by antagonizing degradation by 366 
FBXW711,13,14. Inhibition of Aurora-A by MLN8237 abrogates histone H3S10 phosphorylation 367 
at low drug concentrations (100 nM), which parallel inhibition of Aurora-A catalytic activity12. 368 
In contrast, the MLN8237-dependent decrease in association of mRNA decapping factors 369 
with promoters, the increase in transcription-replication conflicts and activation of ATR 370 
required elevated concentrations of MLN8237, which correspond to levels that destabilize 371 
MYCN12. Since stabilization of MYCN enables it to recruit BRCA1 and transcription 372 
termination factors8, we suggest that both phosphorylation of H3S10 and the ability to 373 
stabilize MYCN enable Aurora-A to prevent transcription-replication conflicts. The findings 374 
are in line with recent observations that Aurora-A has kinase-independent functions during 375 
DNA replication55. We note that transcription-replication conflicts are stochastic and rare 376 
events, hence the expected MYCN- and Aurora-A-dependent effects on histone occupancy 377 
and gene expression averaged over a large cell population are expected to be small, 378 
consistent with both our global and gene-specific analyses10. 379 
 380 
While Aurora-A monotherapy is effective at high doses in models of neuroblastoma and other 381 
MYCN-driven tumors, its efficacy in human patients is limited, which is in part due to a dose-382 
limiting toxicity that is also see in mice 48. We found that inhibition of ATR strongly increased 383 
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DNA replication in MYCN-amplified neuroblastoma cells and thus aggravated double-strand 384 
break formation and apoptosis caused by Aurora-A inhibition42,56. In vivo, the combined 385 
treatment with low and non-toxic doses of Aurora-A and ATR inhibitors rapidly induced 386 
tumor-specific DNA damage and greatly extended survival, with treatment responses 387 
differing between immuno-competent and deficient models. One reason for this difference in 388 
response is that the responses are both due to cell-intrinsic DNA damage and due to 389 
recognition of tumor cells by the host immune system, hence an intact immune response is 390 
critical for an efficient therapeutic response. Additional factors, such as the different 391 
vascularization of orthotopically growing tumors relative to transplanted tumors or 392 
mechanisms that promote tumor cell plasticity57 may affect the therapeutic outcome. Multiple 393 
strategies are currently being explored that target the transcription machinery of pediatric 394 
tumors for therapy. Our finding that a subset of treated mice remains tumor-free for long 395 
periods of time and appears to be cured of neuroblastoma establishes that targeting 396 
transcription-replication conflicts is an effective strategy for the treatment of MYCN-driven 397 
neuroblastomas and possibly other MYCN-driven tumors that can be realized with currently 398 
available inhibitors. Finally, we note that the Aurora-A interaction domain of MYCN is not 399 
conserved in MYC, and the Aurora-A dependent histone H3.3-deposition is specifically 400 
catalyzed by MYCN, not MYC; since individual tumors almost always express and depend on 401 
a single MYC family member, expression of MYCN may provide a straightforward strategy 402 
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Figure Legends 594 
 595 
Figure 1: Aurora-A controls histone H3 phosphorylation in S phase. 596 
a. (Top): Immunoblots of indicated proteins from S phase-synchronized IMR-5 cells that 597 
were treated for 4 h with 100 µM 10058-F4 or DMSO. Data representative of 3 independent 598 
experiments with similar results. (Bottom): Quantitation of relative levels of chromatin-bound 599 
proteins. Shown is the mean ± standard deviation (S.D.). P-values were calculated using 600 
paired two-tailed t-test relative to DMSO (n=3 independent experiments) 601 
b. Immunofluorescence staining of pH3S10, EdU, Cyclin B1 and Hoechst staining (Top): 602 
Pictures illustrating pH3S10 staining in each cell cycle phase. Scale bar is 5 µm. (Bottom): 603 
Quantification of pH3S10 staining in IMR-5 cells treated for 8 h with MLN8237 (100 nM) 604 
relative to control (DMSO) cells; each grey dot represents a cell. In S and G2 phase number 605 
of spots and in mitotic cells intensity of pH3S10 signal compared to DMSO is shown. Shown 606 
is the mean ± S.D. (n≥137 cells examined over 3 independent experiments). 607 
c.  Quantification of pH3S10 staining in IMR-5 cells treated for 8 h with 100 nM 608 
MLN8237 (data are the same as in Figure 1b) or 100 nM AZD1152 relative to control 609 
(DMSO) cells; each grey dot represents a cell. In S and G2 phase number of spots and in 610 
mitotic cells intensity of pH3S10 signal compared to DMSO is shown. Shown is the mean ± 611 
S.D. (n≥390 cells were examined over 3 independent experiments). 612 
d. Metagene plot of ChIP-Rx signal for histone H3.3 and pH3S10 in S phase-613 
synchronized IMR-5 cells treated for 4 h with 1 µM MLN8237 or DMSO. The signal is 614 
centered on the first nucleosome (“+1 dyad”) located downstream of the TSS. Shown is the 615 
mean for 3,000 expressed genes with highest MYCN promoter occupancy. (n=3 independent 616 
experiments).  617 
e. Metagene plot as in (d) for 3,000 expressed genes with lowest MYCN promoter 618 
occupancy (n=3 independent experiments). 619 
f. pH3S10 (left) and histone H3.3 (right) ChIP at indicated loci after 4 h incubation with 620 
MLN8237 (1 µM) in SH-EP and in SH-EP MYCN cells synchronized in S phase. Shown is the 621 
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mean of technical triplicates from one experiment. Data representative of 2 independent 622 
experiments with similar results. 623 
 624 
Figure 2: Aurora-A inhibition induces transcription-replication conflicts. 625 
a. Metagene plot of ChIP-Rx signal for RNAPII pSer2 in S phase-synchronized IMR-5 626 
cells treated for 4 h with MLN8237 (1 µM), MK5108 (1 µM) or DMSO. The signal is centered 627 
on the first nucleosome (“+1 dyad”) located within 300 nt downstream of the TSS. Data show 628 
mean for the 3,000 expressed genes with highest MYCN promoter occupancy (n=2 629 
independent experiments).  630 
b. Metagene plot as in (a) filtered for the 3,000 expressed genes with lowest MYCN 631 
promoter occupancy (n=2 independent experiments). 632 
c.  Bin plots of average RNAPII pSer2 ChIP-Rx occupancy around the first exon-intron 633 
boundary (+/- 200 nt) from S phase-synchronized IMR-5 cells treated for 2 h with MLN8237 634 
(1 µM) or DMSO. Shown is the mean for the 3,000 genes in each bin. Genes were ordered 635 
by MYCN occupancy (n=2 independent experiments). 636 
d. DNA-RNA-Immunoprecipitation (DRIP) using S9.6 antibody, detecting R-loops at the 637 
indicated loci after MLN8237 (1 µM, 8 h) treatment. Incubation with RNaseH1 and IgG were 638 
used as controls for non-specific chromatin binding. Shown is the mean of technical 639 
triplicates from a representative experiment. Data representative of 3 independent 640 
experiments with similar results. 641 
e. DNA-RNA-Immunoprecipitation (DRIP) using S9.6 antibody, indicating R-loops at the 642 
indicated loci after 8 h of 1 µM MLN8237 or 1 µM AZD1152 treatment. Incubation with 643 
RNaseH1 and IgG were used as controls for non-specific chromatin binding. Shown is the 644 
mean of technical triplicates from a representative experiment. Data representative of 2 645 
independent experiments with similar results. 646 
f.  Proximity Ligation Assay between RNAPII and PCNA in asynchronous IMR-5 cells 647 
treated for 8 h with the indicated inhibitors (MLN8237, MK5108 (1 µM), NVP-2 (200 nM) or 648 
Flavopiridol (FP; 200 nM)). Control shows primary antibodies only in cells treated with 1 µM 649 
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MLN8237. (Top): Example pictures of PLA in different conditions. (Bottom): Quantification of 650 
PLA signals. Each dot represents mean PLA signal of all cells in one well compared to 651 
solvent control. Shown is the mean ± S.D.. P-values were calculated comparing treatment to 652 
DMSO using unpaired two-tailed t-test. White line indicates 5 µm (n=6 for control and 653 
MK5108, n=7 for NVP-2, n=8 for FP, n=10 for MLN8237 (100 nM and 1 µM each) 654 
independent experiments). 655 
 656 
Figure 3: Aurora-A/ATR inhibition reduces replication fork progression. 657 
a. pRPA S33 staining in IMR-5 cells treated for 8 h with indicated concentration of 658 
Aurora-A inhibitor. Shown is the mean intensity in each condition ± S.D.; each dot represents 659 
one cell (n≥73 cells examined over 3 independent experiments). P-values were calculated 660 
using unpaired two-tailed t-test, Color indicates significant difference of mean from control 661 
(blue: p=0.0004; red: p<0.0001, DMSO vs. MLN 5 µM p<1.0e-15, DMSO vs. MLN 10 µM 662 
p=1.9e-13). 663 
b. Immunoblots of cell cycle synchronized IMR-5 cells treated for 4 h (S phase) or 8 h 664 
(G2/M phase) with MLN8237 (MLN) and AZD6738 (AZD, 1µM) or DMSO as control. UV light 665 
was used as positive control. Vinculin was used as loading control. Arrow marks specific 666 
band while (*) indicate non-specific bands. Data representative of 3 independent experiments 667 
with similar results. 668 
c. Fork progression speed in IMR-5 cells treated for 3 h with 100 nM MLN8237, 1 µM of 669 
AZD6738 or a combination of both. Experimental setup is shown on top. Cells were 670 
incubated 20 min with CldU, followed by incubation for 1 h with IdU. Gemcitabine (300 nM) 671 
was used as positive control. P-value was calculated using unpaired two-tailed t-test 672 
comparing two conditions (n≥142 fibers were examined over 2 independent experiments). 673 
d.  Representative example pictures of fibers treated as and quantified in (c). 674 
e. Quantification of PLA signal between RNAPII and PCNA in asynchronous IMR-5 cells 675 
treated for 8 h with 10 µM Olaparib. Each dot represents mean PLA signal of all cells in one 676 
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well compared to solvent control. Shown is the mean ± S.D.. P-value was calculated 677 
compared to DMSO using unpaired two-tailed t-test (n=4 independent experiments). 678 
f.  Quantification of fork progression measured by fiber assays of IMR-5 cells pretreated 679 
for 3 h with 100 nM MLN8237, 10 µM of Olaparib or the combination. P-values were 680 
calculated using unpaired two-tailed t-test (n≥128 fibers were examined). 681 
g.  Representative example pictures of fibers treated as and quantified in (c). 682 
 683 
Figure 4: Aurora-A/ATR inhibition induces DNA damage. 684 
a. High-content microscopy-based analysis of MYCN-amplified NGP cells treated for 8 h 685 
with 100 nM MLN8237, 1 µM AZD6738 or a combination and assessed for EdU 686 
incorporation, γH2AX, pKAP1 and pH3S10. Each dot represents a single cell and is color-687 
coded according to mean fluorescent intensity (n≥3,837 cells were examined over 3 688 
independent experiments). A.U. arbitrary units. Quantification is shown in (b). 689 
b. Quantification of γH2AX (upper panel) and pKAP1 (lower panel) signals shown in (a). 690 
P-values were calculated using paired two-tailed t-test comparing DMSO to the different 691 
treatments (n≥3,837 cells were examined over 3 independent experiments). 692 
c. Annexin-V/PI FACS of the indicated cell lines (MYCN non-amplified: SH-EP, SK-NAS, 693 
SH-SY5Y; MYCN-amplified: IMR-5, NGP, IMR-32) treated for 48 h with DMSO, MLN8237 694 
(100 nM), AZD6738 (1 µM) or both. Shown is the mean ± S.D., p-values were calculated 695 
using paired two-tailed t-test comparing MLN8237 to combination (n=3 independent 696 
experiments). 697 
d. DCP1A (left) and EDC4 (right) ChIP at indicated loci after 4 h of 100 nM or 1 µM 698 
MLN8237 treatment in S phase synchronized IMR-5 cells. IgG control was used as control 699 
for antibody specificity. Data are presented as mean of technical triplicates from a 700 
representative experiment. Data representative of 3 independent experiments with similar 701 
results. 702 
 703 
Figure 5: Treatment responses to combined Aurora-A/ATR inhibition. 704 
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a.  Representative sections of tumors of untreated, 24 h treated or 5 days treated TH-705 
MYCN mice showing haemotoxylin and eosin (H&E), Ki67, R-loops, γH2AX, 53BP1, pKAP1 706 
and cleaved caspase 3. The second column on the cleaved caspase staining shows kidney 707 
tissue of tumor-bearing mice treated for the same time. N=4 mice (control, 24 h treatment), 5 708 
mice (5 days treatment). 709 
b. Box plots show quantification of R-loop-, γH2AX-, 53BP1-, pKAP1- and cleaved 710 
caspase 3-positive cells in tumor sections. P-values were calculated using unpaired two-711 
tailed t-test using Welch’s correction (n≥12 sections from the animals described in panel (a) 712 
were evaluated). 713 
c. Representative sections of tumors of untreated, 24 h or 5 days treated TH-MYCN 714 
mice showing H3S10 phosphorylation. Arrows mark mitotic cells. The second row shows 715 
staining of adjacent kidney tissue. Same cohort as described in panel (a).  716 
d. Relative number of pH3S10-positive non-mitotic (left) and mitotic cells (right) shown in 717 
panel b. P-value was calculated using an unpaired two-tailed t-test using Welch’s correction 718 
(n≥12 sections from the animals described in panel (a) were evaluated). 719 
 720 
Figure 6: Therapeutic efficacy of combined Aurora-A/ATR inhibitor treatment.  721 
a. Representative MRI sections of mice at day 0 and day 7 of treatment with vehicle, 722 
MLN8237 (15 mg/kg), AZD6738 (25 mg/kg) or both. Dashed white lines indicate tumor 723 
circumference. N=4 mice (control, AZD6738), 3 mice (MLN8237), 5 mice (combination). 724 
b. Waterfall plot showing relative changes in tumor volume during the first seven days of 725 
the beginning of treatment with indicated drugs. Control animals marked with hash (#) show 726 
measurement at day 4. Mice which survived the treatment for up to 150 days are marked 727 
with an asterisk (*). Each line on the graph represents one mouse.  728 
c. Kaplan Meier survival curve of TH-MYCN mice treated as indicated. AZD6738 was 729 
administered at 25-30 mg/kg every day and MLN8237 at 15 mg/kg on a 5 days on, 2 days off 730 
schedule. Shaded area indicates duration of the combination treatment (ended at 32 days, 731 
56 doses) (N=8 animals for MLN8237 + AZD6738 (30 mg/kg), 4 animals for all other 732 
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experimental cohorts). P-values were calculated using Mantel-Cox log-rank test and are 733 
shown in Extended Data Figure 5g. 734 
 735 
Figure 7: Combination therapy engages the immune system.  736 
a. Relative changes in tumor volume of four MYCN-amplified PDX models during 737 
treatment with indicated inhibitors. Shown is the mean ± S.E.M.. N indicates the animal 738 
number for each experimental cohort. P-values comparing the control to the combination 739 
(indicated by the dashed black line) were calculated using unpaired two-sided t-test. 740 
b. Histology of representative tumor sections showing CD45- and cGAS-positive cells in 741 
tumors of TH-MYCN mice treated with combined Aurora-A/ATR inhibition. N=4 mice (control, 742 
24 h treatment), 5 mice (5 days treatment). 743 
c. Box plots of CD45-(left) and cGAS-positive (right) staining in tumor sections in (d). P-744 
values were calculated using unpaired two-sided t-test using Welch’s correction (n≥12 745 
sections from animals described in panel (b) were evaluated). 746 
d. Relative changes in tumor volume of subcutaneous allografts in NSG or 129SvJ mice 747 
after treatment with vehicle or a combination of AZD6738 (25 mg/kg every day) and 748 
MLN8237 (15mg/kg, 5 days on, 2 days off). Shown is the mean ± S.E.M.. Each group consist 749 
of five animals. P-value comparing the relative tumor volume of NSG and 129SvJ treated 750 
with the combination at day 15 (indicated by a dashed black line) was calculated using 751 
unpaired two-tailed t-test. 752 
e. Model summarizing our findings. For clarity of presentation only one nucleosome is 753 
shown. 754 
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Methods 756 
Further information on research design is available in the Nature Research Reporting 757 
Summary linked to this article. 758 
 759 
Cell culture 760 
Cell lines derived from human neuroblastoma (IMR-5, SH-EP, NGP, SH-EP, SH-SY5Y, SK-761 
NAS) were verified by STR profiling and grown in RPMI-1640 (Thermo Fisher Scientific). 762 
Murine NIH-3T3 cells were grown in DMEM (Thermo Fisher Scientific). Media were 763 
supplemented with 10% fetal calf serum (Sigma-Aldrich and Capricorn Scientific GmbH) and 764 
penicillin/streptomycin (Sigma-Aldrich). All cells were routinely tested for mycoplasma 765 
contamination. For double-thymidine block, cells were treated for 16 h with 2 mM thymidine 766 
(Sigma-Aldrich), released for 8 h into normal medium and then blocked again (2 mM, 16 h). 767 
For release, cells were washed with PBS before medium was added. For nocodazole block 768 
in mitosis, cells were treated for 16 h with 0.6 µg/ml nocodazole (Sigma-Aldrich).32For pulsed 769 
5-ethynyl-2’-deoxyuridine (EdU, Thermo Fisher Scientific) incorporation, cells were incubated 770 
for 30 min in medium containing 10 µM EdU. The Click-iT EdU Alexa Fluor Imaging Kit 771 
(Thermo Fisher Scientific) was used for EdU detection. Inhibitors were used in the following 772 
concentrations according to previous publications as well as length of treatment in our study. 773 
10058-F4: 100 µM; 18, MLN8237: 100 nM or 1 µM 12; MK5108: 1 µM12; AZD6738: 1 µM38; 774 
AZD1152: 100 nM or 1 µM 26; PlaB: 1 µM32,58; NVP-2: 200 nM59; Flavopiridol: 200 nM8,60. 775 
 776 
Immunofluorescence staining 777 
IMR-5 cells were plated in 96-well plates (Greiner). Inhibitors were added for 8 h depending 778 
on the experiment. Cells were fixed and permeabilized with methanol for 20 min. After 779 
removing methanol, cells were blocked with 5% BSA in PBS. Samples were stained with 780 
primary antibody against pRPA S33 (rabbit, A300-246A, Bethyl, 1:400), pH3S10 (rabbit, 06-781 
570, Sigma, 1:500), pH3T3 (rabbit, Cell Signaling, 1:100) or Cyclin B1 (mouse, sc-245, Santa 782 
Cruz, 1:500) in 5% BSA in PBS overnight at 4 °C and after washing incubated with 783 
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secondary antibody (Alexa Fluor 488 and Alexa Fluor 568 from Invitrogen, 1:400) for 1 h at 784 
room temperature (RT). Nuclei were counterstained using Hoechst 33342 (Sigma-Aldrich). 785 
High-throughput pictures were taken with an Operetta® High-Content Imaging System with 786 
20-fold or 40-fold magnification. Images were analyzed using Harmony® High Content 787 
Imaging and Analysis Software. 788 
 789 
Proximity Ligation Assay (PLA) 790 
IMR-5 cells were plated in 384-well plates (Greiner), treated for 8 h with the indicated 791 
inhibitors and fixed with methanol for 20 min. After blocking for 30 min with 5% BSA in PBS, 792 
cells were incubated over night at 4 °C with primary antibody against PCNA (rabbit, ab92552, 793 
Abcam, 1:1,000) and total RNA Polymerase II (mouse, F12, Santa Cruz, 1:1,000). PLA was 794 
performed using Duolink® In Situ Kit (Sigma-Aldrich) according to the manufacturer´s 795 
protocol. Nuclei were counterstained using Hoechst 33342 (Sigma-Aldrich). Pictures were 796 
taken with an Operetta® High-Content Imaging System with 40-fold magnification and 797 
analyzed using Harmony® High Content Imaging and Analysis Software. Sixteen image 798 
fields per well were acquired with a total of at least 1,000 cells per sample. 799 
 800 
Quantitative image-based cytometry (QIBC) 801 
Asynchronously growing MYCN-amplified NGP neuroblastoma cells were grown on sterile 12 802 
mm glass coverslips until they reached a cell density of 70 to 90%. Following an EdU pulse 803 
of 20 min, cells were fixed in 4% formaldehyde for 15 min, washed once in PBS, 804 
permeabilized for 5 min in 0.2% Triton X-100 (Sigma-Aldrich) in PBS, washed twice with PBS 805 
and incubated in blocking solution (filtered DMEM containing 10% FBS and 0.02% sodium 806 
azide) for 15 min. EdU Click-iT reactions were performed prior to primary antibody 807 
incubations according to manufacturer’s recommendations (Thermo Fisher Scientific). 808 
Primary antibodies (γH2AX (mouse, 613402, BioLegend, 1:1,000); pKAP1 S824 (rabbit, 809 
ab70369, Abcam, 1:500); pH3S10 (rabbit, ab5176, Abcam, 1:2,000)) were diluted in blocking 810 
solution and incubated at RT for 2 h. Secondary antibodies (Alexa Fluor 488, 568, and 647 811 
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anti-mouse and anti-rabbit IgG from Thermo Fisher Scientific) were diluted 1:500 in 5% BSA 812 
in PBS and incubated at RT for 1 h. Cells were washed once with PBS and incubated for 10 813 
min with 4’,6-Diamidino-2-Phenylindole Dihydrochloride (DAPI, 0.5 µg/ml) in PBS at RT. 814 
Following three washing steps in PBS, coverslips were briefly washed with distilled water and 815 
mounted on 5 µl Mowiol-based mounting media (Mowiol 4.88 (Calbiochem) in glycerol/TRIS). 816 
Automated multichannel wide-field microscopy for high-content imaging and quantitative 817 
image-based cytometry (QIBC) was performed using the Olympus ScanR System as 818 
described previously61. Images were analyzed with the inbuilt Olympus ScanR Image 819 
Analysis Software Version 3.0.1, a dynamic background correction was applied, and nuclear 820 
segmentation was performed using an integrated intensity-based object detection module 821 
based on the DAPI signal. All downstream analyses were focused on properly detected cell 822 
nuclei containing a 2C-4C DNA content as measured by total and mean DAPI intensities. 823 
Fluorescence intensities were quantified and were depicted as arbitrary units. Within one 824 
experiment, similar cell numbers were compared for the different conditions and 825 
representative single cell scatter plots are shown. Fluorescence intensities were quantified 826 
and are depicted as arbitrary units. Color-coded scatter plots of asynchronous cell 827 
populations as well as statistical analysis were generated using R. 828 
 829 
Immunoblots and immunoprecipitations 830 
Whole cell extracts were prepared using RIPA buffer (50 mM HEPES, 140 mM NaCl, 1 mM 831 
EDTA; 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS) containing protease and 832 
phosphatase inhibitor cocktails (Sigma-Aldrich). Lysates were cleared by centrifugation and 833 
protein concentrations were determined by Bradford or BCA-Assay.  834 
For fractionation, cells were treated as indicated, washed with TBS containing protease and 835 
phosphatase inhibitor cocktails (Sigma-Aldrich) and harvested by centrifugation (300 g, 836 
20 min, 4 °C). Lysis was carried out in sucrose buffer I (10 mM HEPES pH 7.9, 0.34 M 837 
sucrose, 3 mM CaCl2, 2 mM magnesium acetate, 0.1 mM EDTA, 0.5% NP-40) for 20 min at 838 
4 °C with rotation. Nuclei were pelleted (3,900 g, 20 min, 4 °C) and washed once with 839 
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sucrose buffer I without NP-40. Lysis of nuclei was carried out in nucleoplasmic lysis buffer 840 
(20 mM HEPES pH 7.9, 3 mM EDTA, 10% glycerol, 150 mM potassium acetate, 1.5 mM 841 
MgCl2) by performing 20 strokes with a dounce-homogenizer on ice. Lysed nuclei were 842 
incubated 30 min on ice and homogenized with 30 strokes. Benzonase (25 units, Merck) was 843 
added and incubated for 1 h at 16 °C. Unsolubilized chromatin was pelleted by centrifugation 844 
(18,000 g, 30 min 4 °C), resuspended in Lämmli buffer containing Benzonase (5 units) to 845 
release chromatin bound proteins, incubated at RT for 1 h and heated for 15 min at 95 °C. 846 
Protein samples were separated on Bis-Tris gels and transferred to a PVDF membrane 847 
(Millipore). Protein expression was analyzed by immunoblotting with the indicated primary 848 
antibodies listed in the Reporting Summary. Membranes were scanned and analyzed using a 849 
Licor Odyssey scanner and Image Studio (LI-COR Biosciences) or LAS4000 Mini Imaging 850 
system (Fuji). 851 
For immunoblots showing multiple proteins with similar molecular weight, one representative 852 
loading control is shown. Vinculin or actin were used as loading control. 853 
 854 
Flow cytometry analysis (FACS) 855 
For PI-FACS cells were harvested by trypsinization, washed with cold PBS and fixed in 80% 856 
ethanol overnight at −20 °C. After washing with PBS, the cells were resuspended in PBS 857 
with RNase A (24 µg/ml) and propidium iodide (PI, 54 µM) and incubated for 30 min at 37 °C. 858 
For AnnexinV/PI-FACS, the supernatant of the respective culture was combined with cells 859 
harvested by trypsinization and washed with cold PBS. The cell pellet was re-suspended in 860 
100 μl 1x AnnexinV-binding buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) 861 
with AnnexinV/Pacific Blue dye and incubated for 15 min at RT in the dark. Afterwards 400 μl 862 
1x binding buffer containing PI (54 µM) was added and the samples were stored cold and 863 
dark until analysis. Subsequent analysis of all cell cycle related FACS experiments was 864 
performed on a BD FACSCanto II flow cytometer using BD FACSDIVATM Software.  865 
Tumors were dissociated using Collagenase IV (3.2 mg/ml, Worthington # LS004209), 866 
Deoxyribonuclease I (1 mg/ml, Worthington # LS002007), Soybean trypsin inhibitor (2 mg/ml, 867 
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Worthington #LS003587) in Ca/Mg-free PBS, and were incubated with CD45 PE/Cy7 868 
(109830, Biolegend), Live-dead marker (L34975, Invitrogen) and F4/80 block (743282, 869 
BDBioscience). FACS experiments of tumor samples were performed on a BDFACSAria ll 870 
cytometer. 871 
 872 
DNA-RNA-Immunoprecipitation (DRIP) 873 
DRIP was performed as described62. Briefly, cells were digested with 0.5% SDS and 874 
proteinase K overnight. DNA was extracted with phenol/chloroform and precipitated with 875 
ethanol. DNA was digested using a cocktail of restriction enzymes (Bsrg1, EcoR1, HindIII, 876 
SspI, XbaI (NEB)) overnight at 37 °C. For RNaseH-treated sample DNA was additionally 877 
incubated with RNaseH1 (NEB) overnight. DNA was purified as described above. S9.6 878 
antibody (Merck, MABE1095 or Absolute, Ab01137-2.0), which detects RNA/DNA hybrids63, 879 
was coupled to A/G-Dynabeads® (Invitrogen). DNA in 1 x binding buffer (10 mM NaPO4 pH 880 
7.0, 140 mM NaCl, 0.05% Triton X-100) was added to the antibody-coupled beads overnight. 881 
After extensive washing, DNA was eluted with elution buffer (50 mM Tris-HCl pH 8.0, 10 mM 882 
EDTA, 0.5% SDS) and treated for 2 h at 45 °C with proteinase K. After DNA extraction, 883 
locus-specific DRIP signals were assessed by RT-PCR (for primers see section below). 884 
 885 
High-throughput sequencing 886 
ChIP and ChIP-sequencing was performed as described previously4. For spike-in 887 
experiments (ChIP-Rx) 10% of fixed NIH-3T3 mouse cell lines were added before lysis. Cells 888 
were treated with 1% formaldehyde for 5 min at RT following 5 min of incubation with glycine. 889 
After cell lysis (5 mM PIPES pH 8.8, 5 mM KCl, 0.5% NP40), nuclei were resuspended in 890 
RIPA buffer (50 mM HEPES pH 7.9, 140 mM NaCl, 1% Triton-X-100, 0.1% deoxycholic acid 891 
(DOC), 0.1% SDS, 1 mM EDTA containing protease and phosphatase inhibitor cocktail) and 892 
DNA was fragmented to a size <500 bp using a Covaris M220 sonifier. Antibodies (total 893 
RNA-Polymerase II (mouse, Santa Cruz, A10), RNA-Polymerase pSer2 (rabbit, Abcam, 894 
ab5095), H3 (rabbit, Abcam, ab1791), pH3S10 (rabbit, Abcam, ab177218), H3.3 (rabbit, 895 
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Abcam, ab176840)) were bound to Protein A/G-Dynabeads® (Invitrogen) and 896 
immunoprecipitated. After extensive washing, chromatin was eluted with 1% SDS and 897 
crosslinking was reverted overnight. Chloroform/phenol extraction was used for DNA 898 
purification. After DNA extraction occupancy of different proteins were assessed by RT-PCR. 899 
Primers were used for GBA (forward: AGCCCTTCCTCAAGTCTCAT; reverse: 900 
ACTGTGGGAATTCAATCGCC), EIF3B (forward: TGGGTGTGCTGTGAGTGTAG; reverse: 901 
ATGGACAATTCTGAGGGGCA), ACTB (forward: GAGGGGAGAGGGGGTAAA; reverse: 902 
AGCCATAAAAGGCAACTTTCG), TFAP4 (forward: CCGGGCGCTGTTTACTA; reverse: 903 
CAGGACACGGAGAACTACAG), RAN (forward: CCGTGACTCTGGGATCTTGA; reverse: 904 
CAAGGTGGCTGAAACGGAAA), POLG (forward: CTTCTCAAGGAGCAGGTGGA; reverse: 905 
TCATAACCTCCCTTCGACCG), NPM1 (forward: TTCACCGGGAAGCATGG; reverse: 906 
CACGCGAGGTAAGTCTACG), RPS16 (forward: CCGAGCGTGGACTAGACAA; reverse: 907 
GTTAGCCGCAACAGAAGCC), DRG2 (forward: CGTGGGCCAGTACAGCAT; reverse: 908 
CCGGAAGCCAAAGAGAACAG), Centrosome (forward: TCATTCCCACAAACTGCGTTG; 909 
reverse: TCCAACGAAGGCCACAAGA), Intergenic region (forward: 910 
TTTTCTCACATTGCCCCTGT; reverse: TCAATGCTGTACCAGGCAAA), NCL (forward: 911 
CTACCACCCTCATCTGAATCC; reverse: TTGTCTCGCTGGGAAAGG), RCC1 (forward: 912 
AGTGGTCGCTTCTTCTCCTT; reverse: GCATTAGACCCACAACTCCG), NME1 (forward: 913 
GGGGTGGAGAGAAGAAAGCA; reverse: TGGGAGTAGGCAGTCATTCT), PPRC1 914 
(forward: GTGAGGATTAGCGCTTGGAG; reverse: TGCTGTACGTTCCTTTCACC), PTPN23 915 
(forward: CCAGTCTCCGGTCAGTGATT; reverse: CGTATTGTCAAGAGCCGTGG), and 916 
PLD6 (forward: GCTGTGGGTCCCGGATTA; reverse: CCTCCAGAGTCAGAGCCA).  917 
Shown analysis of RT-PCR show mean and standard deviation of technical triplicates as well 918 
as an overlay of each data point to indicate the distribution of the data. 919 
 920 
ChIP sequencing was performed as described in64. Using the NEBNext® ChIP-Seq Library 921 
Prep Master Kit or the NEBNext® UltraII DNA Library Prep Kit for Illumina, purified DNA was 922 
end-repaired, A-tailed, ligated to Illumina adaptors, size-selected (200 bp) and purified with a 923 
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gel extraction kit. DNA fragments were amplified by 15 to 18 cycles of PCR and library size 924 
and amount of library was specified with the Fragment Analyzer (Agilent).  925 
RNA sequencing was performed as described previously65 using an Illumina NextSeq 500. 926 
RNA was extracted using RNeasy mini columns (Qiagen) including on-column DNase I 927 
digestion. mRNA was isolated using the NEBNext® Poly(A) mRNA Magnetic Isolation 928 
Module (NEB) and library preparation was performed with the NEBNext® Ultra™ RNA 929 
Library Prep Kit for Illumina following the instruction manual. Libraries were amplified with 12 930 
PCR cycles and purified using Agencourt AMPure XP Beads (Beckman Coulter). Library 931 
quantification and size determination was performed with the Fragment Analyzer (Agilent). 932 
For 4sU labelled nascent RNA sequencing, IMR-5 cells were cell cycle synchronized using 933 
double thymidine block. At timepoint of release indicated inhibitors were added. 2 h before 934 
harvest cells were incubated with 500 µM of 4sU (Sigma-Aldrich) in RPMI to label nascent 935 
RNA. After 15 min medium was changed. RNA was harvested using Qiagen miRNeasy kit. 936 
After extraction and quantification of total RNA by Nanodrop, an equal amount was labelled 937 
with biotin (Pierce) in presence of DMF-HPDP buffer. Free biotin removal was carried out by 938 
chloroform-isoamyl alcohol extraction after which RNA was resuspended into nuclease free 939 
water. DynabeadsTM MyOneTM Streptavidin C1 beads (Life Technologies) were used for 940 
enrichment of biotinylated RNA, which was then eluted by 100 mM DTT and cleaned by 941 
RNeasy MinElute cleanup kit. Nascent RNA concentration was then measured using 942 
RiboGreen RNA assay kit and equal amount was used for library preparation. Before library 943 
preparation, rRNA was depleted using NEBNext® rRNA Depletion Kit and then all eluted 944 
material was used for NEBNext® Ultra Directional kit with 14 PCR cycles.  945 
All libraries were sequenced for 75 cycles using Illumina NextSeq 500 system. Following 946 
base calling with Illumina’s FASTQ Generation Software v1.0.0 high quality PF clusters were 947 





DNA fiber assay 952 
DNA fiber assays were carried out as previously described66. Newly synthesized DNA was 953 
labeled via treatment with 5-chloro-2-deoxyuridine (CldU, 25 μM, Sigma-Aldrich) for 20 min, 954 
followed by 5-iodo-2-deoxyuridine (IdU, 50 μM, Sigma-Aldrich) for 1 h, in the presence of 955 
inhibitors as indicated. Cells were lysed by spreading buffer (200 mM Tris pH 7.4, 50 mM 956 
EDTA, 0.5% SDS) and DNA fibers spread on glass slides prior to fixation in a 957 
methanol:acetic acid solution. After DNA denaturation by 2.5 M HCl, CldU- and IdU-labelled 958 
tracts were detected by immunostaining using mouse anti-BrdU (B44, BD), rat anti-BrdU 959 
(BU1/75, ICR1, Abcam) antibodies and Alexa Fluor 488-conjugated goat anti-mouse IgG, 960 
Alexa Fluor 555-conjugated goat anti-rat IgG (Thermofisher) as secondary antibodies. DNA 961 
fibers were visualized with fluorescence microscopy (Axio Scope A1 microscope, Zeiss) and 962 
analyzed with ImageJ. Statistical testing was performed using Graph Pad Prism v.6. 963 
Unpaired Student’s t-test was calculated with an assumed significance for p-values ≤ 0.05. 964 
 965 
Animal experiments 966 
All animal experiments with transgene TH-MYCN mice or tissue were approved by The 967 
Institute of Cancer Research Animal Welfare and Ethical Review Body and performed in 968 
accordance with the UK Home Office Animals (Scientific Procedures) Act 1986, the United 969 
Kingdom National Cancer Research Institute guidelines for the welfare of animals in cancer 970 
research and the ARRIVE (animal research: reporting in vivo experiments) guidelines. 971 
Transgenic TH-MYCN mice were genotyped to detect the presence of human MYCN 972 
transgene47. The study was performed using both male and female homozygous mice, which 973 
developed palpable tumors at 35 to 45 days with a 100% penetrance. Tumor development 974 
was monitored weekly by palpation by an experienced animal technician. Mice with palpable 975 
tumors were then enrolled (day 0) in the study. The tumor volume was subsequently 976 
monitored by MRI at day 0 and 7. Mice were treated with 25 mg/kg or 30 mg/kg of AZD6738 977 
(p.o., daily), 15 mg/kg MLN8237 (p.o., in a ‘five days on, two days off’ schedule) or vehicle 978 
control, to a maximum of 56 doses. MLN8237 was dissolved in 10% (2-Hydroxypropyl)-β-979 
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cyclodextrin,1% Sodium hydrogen carbonate and AZD6738 was dissolved in 10% DMSO, 980 
40% propylene glycol, 50% water. Mice were allowed access to sterile food and water ad 981 
libitum. 982 
For combination studies of MLN8237 with PARP inhibitor, Olaparib was dosed at 45 mg/kg 983 
(p.o., daily for 5 days). Prior to dosing, Olaparib was made fresh from stock solution (50 984 
mg/ml in DMSO) and diluted with 10% 2-hydroxy-propyl-beta-cyclodextrin [HPCD]. Tumors 985 
were collected 2 hours after last dose on Day 5. 986 
MR images were acquired on a 1 Tesla M3 small animal MRI scanner (Aspect Imaging, 987 
Shoham, Israel) or a 7 Tesla Bruker MRI. Mice were anaesthetized using isoflurane delivered 988 
via oxygen gas and their core temperature was maintained at 37 °C. Anatomical fat-989 
suppressed T2-weighted coronal images (TE=9 ms (1T) or 36 ms (7T), TR=4500 ms) were 990 
acquired from 20 contiguous 1-mm-thick slices through the mouse abdomen. Tumor volumes 991 
were determined using segmentation from regions of interest drawn on each tumor-992 
containing slice using Horos medical image viewer. 993 
One million tumor cells from a TH-MYCN tumor were injected subcutaneously into the right 994 
flank of immunocompetent 129SvJ mice, immunodeficient NSG or nude mice (female, 6 995 
weeks old) to established murine allograft model. Mice bearing allografts with a mean 996 
diameter of 4-5 mm were treated as in the TH-MYCN model. Studies were terminated when 997 
the mean diameter of the tumor reached 15 mm. Tumor volumes were measured by Vernier 998 
caliper across two perpendicular diameters, and volumes were calculated according to the 999 
formula: V = 4/3π [(d1 + d2) / 4]3. 1000 
 1001 
All experiments with patient derived xenografts were conducted according to the institutional 1002 
animal protocols and the national laws and regulations. The experiments were conducted as 1003 
previously described in four replicates67. In short, NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac mice 1004 
(Taconic) or Rj:NMRI-Foxn1 nu/nu (Janvier labs) mice (female, 6-10 weeks old) were used to 1005 
perform all patient-derived xenograft experiments. Prior to the experiments, patient tumors 1006 
were serially transplanted in mice at least three times. Caliper measurement was used to 1007 
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monitor tumor growth. Tumor volume was calculated with the formula length x width 2 / 2. 1008 
Mice were sacrificed with cervical dislocation when tumor size exceeded 2,000 mm³. Drugs 1009 
were dissolved in DMSO/Tween/0.9%NaCl. Mice were treated with 50 mg/kg of AZD6738 1010 
(p.o., daily), 7.5 mg/kg MLN8237 (p.o., in a ‘five days on, two days off’ schedule), the 1011 
combination or vehicle control for two weeks. 1012 
All mice were housed in pathogen-free barrier conditions under 12 h light–dark cycles and 1013 
with temperature and humidity set points at 20–25 °C and 30–70%, respectively.  1014 
 1015 
Immunohistochemistry 1016 
For immunohistochemical analysis, samples were embedded in paraffin and sectioned at 1017 
6 µm using a microtome (Leica). Sections were deparaffinized, re-hydrated, and subjected to 1018 
high-temperature antigen retrieval at pH 9.0 for pKAP1 or pH 6.0 for all other stainings. 1019 
Sections were washed, and species-appropriate secondary antibody reagents were applied 1020 
(rabbit: Super Boost goat anti-rabbit poly HRP, mouse: MOM Kit, rat: Vectastatin Elite ABC 1021 
Peroxidase Kit). HRP-conjugated secondary antibodies were visualized by DAB staining 1022 
(Vector Laboratories). Stainings were recorded using Panoramic Desk scanner and analyzed 1023 
using Case Viewer software (3D HISTECH). For scoring of tumor sections at least five 1024 
pictures per tumor section were extracted and blindly scored according to a scale from 0-3.  1025 
 1026 
Bioinformatical analysis and statistics 1027 
All bioinformatical analysis were done with commercial tools. Base calling was performed 1028 
using Illumina’s FASTQ Generation software v1.0.0 and sequencing quality was tested using 1029 
the FastQC script. For ChIP-sequencing, reads were mapped independently to the human 1030 
hg19 and murine mm10 (spike-in) genome using Bowtie168 with default parameters. A spike-1031 
in normalization factor was calculated by dividing the number of mapped reads of the spike-1032 
in of the smallest sample by the number of mapped reads of the spike-in for each sample. 1033 
For each sample, this factor was multiplied by the number of reads that map to the human 1034 
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genome and all bam files for subsequent analysis were adjusted to this read count. 1035 
SAMtools69 were used for manipulating bam-file (indexing, subsampling and generation of 1036 
bedgraph-files). Peak calling was performed using MACS1470 and bedgraph files were 1037 
generated using the genomecov function from BEDtools. 1038 
Traveling ratios for RNAPII ChIP-seq were calculated by counting reads with BEDtools 1039 
“intersectBed”71 around the TSS (-30 to +300 bp) and within gene bodies (+300 bp to TES) of 1040 
Ensembl genes. Read density graphs were obtained using the computeMatrix function from 1041 
DeepTools72. Gene body counts were normalized to the length of the gene and TSS counts 1042 
were divided by gene body counts. Metagene window plots were generated with ngs.plot.r 73. 1043 
The shaded area corresponds to standard errors. First exon/intron boundaries were 1044 
extracted from the GRCh37 annotation and nucleosome coordinates from the published data 1045 
sets GSM1838910 and GSM183891174. Pause sites and MYCN-activated and repressed 1046 
genes were as defined in Herold et al. (2019). Ideogram showing distribution of ChIP-seq 1047 
data on chromosomes were visualized using RIdeogram 75. 1048 
For mRNA-sequencing, reads were mapped to hg19 using Tophat2 76 and Bowtie2 68 and 1049 
samples were normalized to the number of mapped reads in the smallest sample. Reads per 1050 
gene were counted using the “summarizeOverlaps” function from the R package 1051 
“GenomicAlignments” using the “union”-mode and Ensembl genes. Non- and weakly 1052 
expressed genes were removed (mean count over all samples <1). Differentially expressed 1053 
genes were called with edgeR and p-values were adjusted for multiple-testing using the 1054 
Benjamini-Höchberg procedure. Gene set enrichment analysis (GSEA)51 were done with the 1055 
“Hallmark” databases from MSigDB77, 1,000 permutations and default settings. Browser 1056 
tracks were created using Integrated Genome Browser. 1057 
4sU-sequencing analysis was performed as previously described32. To determine the effect 1058 
of drug treatment on splicing efficiency, all experimental repeats for each condition were 1059 
combined, and for each gene the fraction of spliced reads relative to total reads was 1060 
calculated. Each experimental condition (drug treatment) was then compared to the DMSO 1061 
control using both t test and Wilcoxon matched-pairs signed rank test in GraphPad Prism. 1062 
 49
To determine the effect of MLN8237 treatment on total and pSer2 RNA Pol2 distribution over 1063 
the downstream pause site (n=7,760) or the first exon-intron boundary of expressed genes 1064 
(n=64,764), spike-normalized samples were processed with bedtools intersect to count the 1065 
number of reads over a 400-nt window centered on the downstream pause site or the exon-1066 
intron boundary, respectively. The corresponding MLN8237- and DMSO-samples were then 1067 
compared to each other using the Mann-Whitney test in GraphPad Prism. To stratify genes 1068 
for affinity to MYCN, MYCN ChIPseq reads from S phase synchronized and DMSO treated 1069 
IMR-5 cells were counted in a 600 bp window centered at the TSS using BEDtools intersect. 1070 
Lists of downstream pause sites belonging to the top 3,000 or bottom 3,000 MYCN bound 1071 
genes were obtained by intersecting the corresponding lists, restricted to genes with minimal 1072 
expression in IMR-5 cells.  1073 
In box plots central line shows median and the borders of the boxes show the interquartile 1074 
range of the plotted data. The whiskers extend to 1.5 x the interquartile range and outliers 1075 
are shown as dots. Box plots are shown in Figure 3 c and f, Figure 4 b, Figure 5 b and d, 1076 
Figure 7 c, Extended Data Figure 4 a and i, Extended Data Figure 5 a, and Extended Data 1077 
Figure 6 b. 1078 
 1079 
Statistics and Reproducibility 1080 
Information on statistical tests used, numbers of samples, definitions of error bars and 1081 
statistical measures displayed in the graphs are provided in the caption of the figure.  1082 
Sample size depended on experiments. Microscopy experiment aimed to acquire at least 45 1083 
cells per conditions. Fiber assay aimed to record at least 100 fibers per condition. Analysis of 1084 
this number of cells or fibers was sufficient to obtain normal distribution of the data and 1085 
reliable mean.  1086 
All animal experiments were done with at least 3 animals per condition. Animals were 1087 
randomized for treatment to ensure each group has the same starting point. For evaluation of 1088 
immunohistochemistry pictures were blindly scored by several independent people.  1089 
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No data were excluded from the analyses. Statistical tests were performed using Prism 1090 
(GraphPad) or R.  1091 
 1092 
Data Availability 1093 
ChiP-sequencing as well as RNA-sequencing data is available at the Gene Expression 1094 
Omnibus under the accession number GSE144288. Previously published sequencing data, 1095 
that we re-analyzed here are available under accession code GSM1838910 and 1096 
GSM183891174. Source data for all Figures and Extended Data Figures have been provided 1097 
as Source Data files. All other data supporting the findings of the study are available from the 1098 
corresponding authors on request. 1099 
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